Generative AI stands to unlock significant economic value for the pharmaceutical and medical-product industries, but only if the underlying data can be trusted.

As per the Gartner D&A Summit 2026, at present, just 37 percent of firms feel that they have the capability to govern their data for AI purposes effectively. Considering that even the development of a single drug costs over $2 billion in an industry like this and everything has to be verified against regulatory standards, this is still the biggest barrier to utilizing the benefits of artificial intelligence. 

Pharma data not only has to be accurate but ALCOA+ compliant, traceable throughout its entire lifecycle, and ready for any unplanned audit by either the FDA or EMA. Most organizations assume the fix is better tools.

The real gap is usually ownership and accountability, long before it is technology. If a breach of data integrity is enough to lead to a Complete Response Letter or a Form 483 observation for one batch or clinical file, then governance is the backbone from which all other elements, even AI, hang. Below are 10 ways to narrow the gap that pharmaceutical companies currently have.

• Align Your Data Governance Strategy for Pharma with GxP and Regulatory Frameworks

The pharmaceutical industry has to follow some of the toughest norms when it comes to its data management system. These include FDA 21 CFR Part 11, EU Annex 11, HIPAA, GDPR, and ICH norms. Other than these norms, there is one special thing about the pharma industry known as GxP compliance – GLP/GCP/GMP. Many organizations tend to learn about data governance problems when it comes to audits, at which point the fix becomes far more expensive. Map your data practices to these regulations as early as possible and make a simple table that tells you which regulation and GxP standard needs to be adhered to with which type of data and controls required. This should remain a living document and be reviewed every quarter as new regulations appear.

• Define Ownership Over the Data 

Imagine being asked by an FDA auditor who is in charge of a particular dataset being used in a submission, and everyone on the line is clueless about it. It happens much more often than the average pharma company wants to acknowledge, especially when the data is being utilized by the clinical, R&D, manufacturing, and sales departments. According to a 2026 worldwide survey of data executives, 76% state that their AI governance framework has not been able to keep up with the rate at which people have been using the technology. One of the main reasons why this has occurred is the absence of data owners, since when there is no owner for a particular dataset, no one has the power to improve the problem. Each category of the data should have only one owner (data policy maker) and one steward (data policy enforcer).

• Set Data Quality Criteria Rooted in Pharmaceutical Data Governance Standards

Low-quality data not only causes confusion, but it is also costly, and health care and pharmaceuticals are always among the most expensive industries whenever there is a breach in the quality of their data. When it comes to pharmaceuticals, their data needs to be of ALCOA+ quality: Attributable, Legible, Contemporaneous, Original, Accurate, in addition to Complete, Consistent, Enduring, and Available. Ensure that the data you generate meets these requirements at the time of generation and not after a while. Checking data quality automatically at the time of ingestion is crucial.

• Build a Pharma Data Governance Framework That Scales

Do not attempt to govern everything right from the start. Gartner predicts that 50% of companies will use AI agents in managing their governance policies by 2030, but few pharma companies have been able to achieve that mark. Start small; focus on a single domain and excel at it. A maturity model can show you how well your organization is doing:

Most pharma companies sit at Level 1 or 2.

• Trace Sources for Your Data

Regulators require that every number you submit be traceable back to its source: whose data it is, what changes were made, and when. This lifecycle data traceability is the backbone of inspection readiness. If any single data point among the 10,000 pages presented is challenged without a speedy reaction, there will be a waste of time. Automation of the entire process through your system should start by prioritizing the data points which include regulatory submissions, pharmacovigilance reports, and manufacturing batches.

• Manage Access to Sensitive Information 

 Pharmaceutical firms maintain some of the most sensitive information in existence – patient files, drug formulations, and clinical trial results. Those companies that have robust AI security and access management systems in place can detect breaches more quickly and more cost-effectively than those firms that depend on manual checks. Classify information according to sensitivity, depending on your GxP levels, as patient-level clinical information requires different access controls from commercial analysis.

• Enterprise Data Governance for Pharmaceuticals: Connect Systems So Data Can Flow

The average pharmaceutical organization has more than 30 individual systems including laboratory notebooks, trial management, ERP, quality management, CRM and others. The lack of integration between these systems results in inefficient searching for necessary information and decision making based on the wrong information. The answer is connecting your systems into a unified data environment with master data governance at the core: standardized product hierarchies, harmonized site and supplier records, and consistent identifiers across clinical and commercial systems. Companies like Polestar Analytics help pharma organizations integrate commercial, supply chain, and operational data into one connected ecosystem. Start by mapping data flows across your top 5-7 systems.

• Leverage AI-Driven Data Governance in Pharma

 According to Gartner, spending on AI governance platforms will rise to $492 million by 2026, exceeding $1 billion by 2030. In essence, this implies the use of AI applications that identify flaws in safety reporting, detect manufacturing processes that are outside the specification range as they occur, and label governed data, rather than the individuals who make the decisions as to what constitutes ‘compliance.’ Go for products that control, categorize, assess, and track data lineage. Utilize AI to augment your governance team’s capabilities, not replace them.

• Train All Your People, Not Only IT Ones

Lab scientists, regulators, and manufacturing employees deal with governed data regularly; however, none of them received any training in data governance. This is perhaps the most underestimated gap in drug administration governance, and this is where the problem of inspection readiness usually occurs. Offer training that suits individual roles. For instance, a clinical data manager requires a different expertise compared to a QC Analyst who examines the audit trail or manufacturing operator. Name one or two governance advocates per department who can help peers navigate governed data and serve as a bridge between policy and day-to-day operations.

• Audit Consistently to Strengthen Data Governance in the Pharmaceutical Industry

Perform quarterly reviews of data quality, security controls, and compliance with policy. According to Gartner, by 2028, 50 percent of businesses will implement a zero trust framework to govern their data due to the increasing number of unverified data generated through AI processes that are used by enterprises. Moreover, as the industry transitions from Computer System Validation (CSV) to Computer Software Assurance (CSA) by the FDA, ensure that your audit process is aligned with your system validation lifecycle. Track key performance indicators such as data completeness, speed of resolving access issues, and the number of audit findings linked to governance gaps.

How Polestar Analytics Helps Build a Stronger Data Governance Foundation

Pharmaceutical data governance requires more than policies and compliance frameworks. It requires the data infrastructure, integration, and analytics capabilities to enforce those policies across complex data environments. Polestar Analytics helps pharmaceutical organizations build this foundation by connecting data across commercial, operational, and supply chain systems, improving data visibility and quality, and enabling AI-ready data environments. By bringing data, analytics, and enterprise planning together, Polestar Analytics helps organizations move toward more trusted, connected, and actionable data governance.

Read More: How to Choose the Right Web Hosting in India for Your Online Business

Final Thought

These data governance best practices determine whether AI initiatives realize their full potential value or fall short of it entirely. Since only 37% of companies are ready to embrace this revolution today, there is great potential for those who will start to act now. Focus on these 10 approaches but view them as an integrated whole.

Frequently Asked Questions About Pharmaceutical Data Governance

Q1. What is pharmaceutical data governance, and why is it important?

Pharmaceutical data governance ensures data accuracy, integrity, security, and regulatory compliance across pharma operations. It helps organizations meet GxP, FDA, and EMA requirements while building trusted, AI-ready data environments.

Q2. What are the key data governance standards for pharmaceutical companies?

Key standards include ALCOA+, FDA 21 CFR Part 11, EU Annex 11, GxP (GLP, GCP, GMP), HIPAA, GDPR, and ICH guidelines. These ensure data integrity, traceability, security, and compliance throughout the data lifecycle.

Read More: AI in Medical Manufacturing: Advancing Precision Through Intelligent Systems

Q3. How can AI improve data governance in the pharmaceutical industry?

AI-driven data governance helps pharmaceutical companies automate data quality checks, monitor data lineage, detect anomalies, and strengthen compliance. It also improves data accessibility and prepares enterprise data for reliable AI adoption.